- Home
- AQN vs PRAX Comparison
AQN vs PRAX Comparison
Compare AQN & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AQN
- PRAX
- Stock Information
- Founded
- AQN 1988
- PRAX 2015
- Country
- AQN Canada
- PRAX United States
- Employees
- AQN N/A
- PRAX N/A
- Industry
- AQN Electric Utilities: Central
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- AQN Utilities
- PRAX Health Care
- Exchange
- AQN Nasdaq
- PRAX Nasdaq
- Market Cap
- AQN 4.5B
- PRAX 4.0B
- IPO Year
- AQN 1998
- PRAX 2020
- Fundamental
- Price
- AQN $5.59
- PRAX $164.64
- Analyst Decision
- AQN Hold
- PRAX Strong Buy
- Analyst Count
- AQN 6
- PRAX 12
- Target Price
- AQN $6.46
- PRAX $206.17
- AVG Volume (30 Days)
- AQN 4.2M
- PRAX 1.6M
- Earning Date
- AQN 11-07-2025
- PRAX 11-05-2025
- Dividend Yield
- AQN 4.65%
- PRAX N/A
- EPS Growth
- AQN N/A
- PRAX N/A
- EPS
- AQN N/A
- PRAX N/A
- Revenue
- AQN $2,378,238,000.00
- PRAX $7,463,000.00
- Revenue This Year
- AQN $3.21
- PRAX N/A
- Revenue Next Year
- AQN $3.68
- PRAX $44.43
- P/E Ratio
- AQN N/A
- PRAX N/A
- Revenue Growth
- AQN 2.87
- PRAX 364.98
- 52 Week Low
- AQN $4.19
- PRAX $26.70
- 52 Week High
- AQN $6.24
- PRAX $206.71
- Technical
- Relative Strength Index (RSI)
- AQN 41.08
- PRAX 59.98
- Support Level
- AQN $5.46
- PRAX $167.03
- Resistance Level
- AQN $5.84
- PRAX $206.36
- Average True Range (ATR)
- AQN 0.11
- PRAX 15.38
- MACD
- AQN -0.04
- PRAX -2.96
- Stochastic Oscillator
- AQN 21.95
- PRAX 19.61
About AQN Algonquin Power & Utilities Corp.
Algonquin Power & Utilities Corp is a Canada-based diversified international generation, transmission, and distribution company. The company's operations are organized across two business units consisting of the Regulated Services Group, which owns and operates a portfolio of regulated electric, water distribution and wastewater collection, and natural gas utility systems and transmission operations in the United States, Canada, Bermuda, and Chile; and the Hydro Group, which consists of hydroelectric-generating facilities located in Canada. It generates the majority of its revenue from the Regulated Services Group segment.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.